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Abstract. SIRT1, a class III histone deacetylase, plays a 
critical role in regulating cancer cell growth, migration 
and invasion, which makes it a potential target for cancer 
therapeutics. In this study, we screened derivatives of several 
groups of natural products and identified a novel SIRT1 
inhibitor JQ-101, a synthetic derivative of the polyprenylated 
acylphloroglucinol (PPAP) natural products, with an IC50 for 
SIRT1 of 30 µM in vitro, with 5-fold higher activity for SIRT1 
vs. SIRT2.  Exposure of tumor cells to JQ-101 significantly 
enhanced acetylation of p53 and histone H4K16 at known 
sites of SIRT1 deacetylation, validating SIRT1 as its cellular 
target. JQ-101 suppressed cancer cell growth and survival 
by targeting SIRT1, and also exhibited selective cytotoxicity 
towards a panel of human tumor cell lines, while producing 
no toxicity in two normal human cell types at comparable 
concentrations. JQ-101 induced both apoptosis and cell 
senescence, and suppressed cancer cell invasion in vitro. In 
summary, we have identified JQ-101 as a new SIRT1 inhibitor 
which may have potential application in cancer treatment 
through its ability to induce tumor cell apoptosis and senes-
cence and suppress cancer cell invasion.
Introduction
SIRT1 is a nicotinamide adenine dinucleotide (NAD)-
dependent histone deacetylase that has been reported to play an 
important role in a variety of physiological processes including 
aging, metabolism, cell survival and carcinogenesis (1-6). 
Moreover, there is growing evidence strongly suggesting 
that SIRT1 has a role in cancer progression (7-14). SIRT1 
suppresses apoptosis and cell senescence and also promotes 
cell migration and invasion (14-18), angiogenesis (19,20), and 
drug resistance in multiple models (7-10). In vivo studies show 
that SIRT1 inhibition suppresses tumor growth, metastasis and 
progression in several cancer types, including prostate, breast 
and neuroblastoma (11,12,14). In addition, SIRT1 overexpres-
sion has been shown to correlate with poor prognosis in several 
cancer types, including large B-cell lymphoma (21), prostate 
cancer (18,22), pancreatic cancer (23), gastric cancer (24,25), 
breast cancer (26), hepatocellular carcinoma (27), colorectal 
cancer (28) and lung cancer (29). Collectively, these results 
suggest an important role for SIRT1 in cancer growth and 
progression. SIRT1 inhibitors are therefore of significant 
interest as potential therapeutic agents.
Several inhibitors of SIRT1 have been reported, including 
nicotinamide (30), sirtinol (31), cambinol (32), EX-527 (33), 
Tenovin-6 (34), splitomycin (35), toxoflavin (36), saler-
mide (37), 2-anilinobenzamides (38) among other compounds. 
These SIRT1 inhibitors can induce selective cytotoxicity in 
cancer cells in vitro (31,32,34-36,38,39). In addition, several 
SIRT1 inhibitors have been tested in cancer xenograft mouse 
models (32,34,40). Cambinol was well tolerated in mice and 
significantly inhibited the growth of Burkitt lymphoma xeno-
grafts (32). Tenovin-6 suppressed tumorigenesis of melanoma 
and N-Myc-induced neuroblastoma (34), and inauhzin, a 
phenothiazine, reduced colon xenograft growth (40). These 
results provide proof-of-concept examples that SIRT1 inhibi-
tion may be an effective modality in cancer therapy.
Here we report the identification of a new SIRT1 inhibitor, 
JQ-101, which induces cancer cell apoptosis and senescence, 
suppresses cancer cell invasion, and exerts cancer-specific 
cytotoxity, repressing tumor cell growth.
Materials and methods
Cells, antibodies and reagents. All cancer and normal 
cells lines were obtained from the American Type Culture 
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Collection (Manassas, vA). LNCaP, PC3, Ramos, Jurkat, 
H1299 and MRC5 cells were maintained in RPMI-1640 
medium with 10% FBS (HyClone, CO). H460, A549, ZR75 
and MDA231 cells were maintained in DMEM medium with 
10% FBS. PZ-HPv-7 cells were maintained in Keratinocyte 
Serum-Free Medium supplemented with Epidermal Growth 
Factor (Invitrogen, Carlsbad, CA).
Antibodies to SIRT1 (sc-74504) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA). Antibodies to Ac-p53, 
p53, Ac-Histone H4 and H4 were purchased from Millipore 
(Billerica, MA). Antibodies to β-actin were purchased from 
Sigma-Aldrich (St. Louis, MO). Sirtinol was purchased from 
Sigma-Aldrich.
Chemical synthesis of polyprenylated acylphloroglucinol 
(PPAP) analogues. JQ-101, JQ-2, JQ-3, JQ-4, JQ-5,JQ-6, 
JQ-7, JQ-8, JQ-9, JQ-10, JQ-11, JQ-31, JQ-32, JQ-33 and 
JQ-34 (Fig. 1) are simplified analogues of the type B PPAP 
natural product clusianone and were synthesized using our 
reported procedure involving tandem alkylative dearomati-
zation-annulation of acylphloroglucinols to rapidly construct 
the bicyclo[3.3.1] nonane-1,3,5-trione core (41). BM001, 
BM002, BM003, BM004, BM005, BM006, BM007, BM008, 
BM01810, BM01817, BM01847, BM-01-1005, BM-01-1013F2, 
BM-01-1011, BM-01-1022 and related bicyclo[2.2.2] 
octadiones (Table Ι) were synthesized using the reported 
method involving Mn(III)/Cu(II)-mediated oxidative radical 
cyclizations of dearomatized phloroglucinol substrates (42). 
Compounds QZ-2001-2005, analogues of the type A PPAP 
nemorosone, were prepared as intermediates during the course 
of our chemical synthesis of 7-epi-nemorosone (43).
SIRT1 and SIRT2 activity analysis and small molecule 
screening. The Cayman hSIRT1 activity assay kit (SIRT1 
Direct Fluorescent Screening Assay Kit, cat. no. 10010401) and 
hSIRT2 activity assay kit (SIRT2 Direct Fluorescent Screening 
Assay Kit, cat. no. 700280) were used to quantitate the IC50s 
of the SIRT inhibitors. The assay was carried out according to 
the manufacturer's instructions. All compounds were preincu-
bated with the hSIRT1/hSIRT2 proteins before commencing 
the reaction through the addition of the ‘Fluor de Lys’ 
deacetylase substrate. Deacetylation of K382-p53/K320-p53 
was used as a marker of HDAC activity. Fluorescence was 
read (Ex 360 nm/Em 460 nm) using Synergy HT Multi-Mode 
Microplate Reader (BioTek). Assays were repeated in tripli-
cate. Quantitation of acetylation was derived from the levels 
of fluorescence (displayed in arbitrary fluorescence units), and 
the percentages of inhibition were calculated from the arbi-
trary fluorescence unit of the treated assays and non-treated 
controls. The IC50 was determined  using GraphPad Prism 6.0.
Establishment of stable SIRT1-knockdown cell lines. The 
Phoenix packaging cell line was transfected with shRNA 
expression plasmids pSUPER.retro.puro-SIRT1 (5'-GATGAA 
GTTGACCTCCTCA-3') or pSUPER.retro.puro-non-targeting 
shRNA control separately, using Lipofectamine 2000 
(Invitrogen). After 48 h, the medium containing retrovirus was 
collected, filtered, treated with polybrene and transferred to 
LNCap or H460 cell cultures. Infected cells were selected with 
puromycin and the stably-infected colonies were pooled.
Immunoblot analysis. Cells were lysed with 1% Nonidet P-40 
lysis buffer (1% NP-40, 150 mM NaCl, 50 mM Tris-HCl) with 
protease inhibitor (Roche Diagnostics). Protein samples were 
subsequently separated on an 8% SDS-polyacrylamide gel 
and analyzed with anti-Ac-p53, anti-p53, anti-SIRT1, anti-Ac-
Histone H4, anti-H4 or β-actin antibodies.
Cell viability assay. MTS (Promega, G3580) assays were used 
to quantify cell viability. Cells were plated at a density of 104 
cells/well on 96-well plates and exposed to various concentra-
tions of JQ-101, ranging from 5 to 125 µM, for 72 h. A total of 
20 µl MTS CellTiter96Aqueous one solution reagent was added 
to the medium for 1 h, and the absorbance was read at 490 nm.
Apoptosis analysis by FACS. The cultured cells were tryp-
sinized, collected and labeled with Annexin v antibody and 
PI. The procedure for cell labeling followed the Annexin v 
kit instructions (Annexin v-PE Apoptosis Detection Kit I, 
BC Pharmingen, cat. no. 559763). The labeled samples were 
further analyzed with flow cytometry.
SA-β-gal staining. The cells were seeded at 30% confluence, 
and JQ-101 was added to a final concentration 50 µM. At 4 days 
after the addition of JQ-101 to the culture media, the cells were 
washed with phosphate-buffered saline (PBS) and fixed with 
PBS containing 2% formaldehyde and 0.2% glutaraldehyde 
for 10 min. The cells were then incubated at 37˚C overnight 
with staining solution [40 mM citric acid sodium phosphate, 
pH 6.0, 1 mg/ml 5-bromo-4-chloro-3-isolyl-β-D-galactoside 
(X-gal, Fisher, Pittsburgh, PA), 5 mM potassium ferricyanide, 
150 mM NaCl, 2 mM MgCl2]. SA-β-gal-positive cells were 
enumerated by microscopy.
Cell invasion assay. Cell invasion activity of cancer cells was 
assessed using BD BioCoat Matrigel Invasion Chambers (BD 
cat. no. 354480). Briefly, the cells were trypsined, washed 
with PBS, and resuspended in media containing 1% FBS at a 
density of 5x104 cells/ml. A total of 500 µl of cells suspended 
in medium containing JQ-101 or DMSO (vehicle control) was 
Table I. Cytotoxicity measurement of JQ-101 in multiple 
cancer/normal cell lines.
Cancer cell lines IC50 (µM)
LNCaP   20
Jurkat   25
H460   30
Ramos   33
A549   40
MDA-MB-231   60
ZR75   66
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Figure 1. Synthesized and screened compounds. A panel of synthesized analogues of the type B PPAP natural product clusianone and the type A PPAP natural 
product nemorosone. The compounds were synthesized with a procedure involving tandem alkylative dearomatization/annulation of acylphloroglucinols or 
employing Mn(III)/Cu(II)-mediated oxidative radical cyclizations of dearomatized phloroglucinol substrates.
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placed in the upper chamber coated with matrigel and 500 µl 
of culture media was added to the lower chamber of the trans-
well. After 48 h of incubation at 37˚C, the transwells were 
removed from the 24-well plates and stained with Diff-Quick 
solution. The invading cells were enumerated by microscopy.
Results
Design, synthesis and evaluation of SIRT1 inhibitors based on 
polyprenylated acylphloroglucinol (PPAP) natural products. 
Polyprenylated acylphloroglucinols (PPAPs) are a family of 
natural products that possess a wide range of different biolo-
gical activities (44). There are more than 100 PPAPs discovered 
to date. Most of these were isolated from plants and trees from 
Clusiaceae (Guttiferae). PPAPs are divided into three types 
(A, B and C), depending on the position of the acyl group 
on the bicyclic core (44). It has been reported that the PPAPs 
guttiferone G and aristoforin have SIRT1 inhibitory activity, 
although little biological function has been shown (39). we 
synthesized a panel of derivatives of PPAP compounds using 
our reported procedure involving tandem alkylative dearoma-
tization/annulation of acylphloroglucinols to rapidly construct 
the bicyclo[3.3.1] nonane-1,3,5-trione core (41) or employing 
Mn(III)/Cu(II)-mediated oxidative radical cyclizations of 
dearomatized phloroglucinol substrates (42).
Using a fluorogenic substrate, we performed a biochem-
ical-based inhibitory assay with recombinant SIRT1 and 
SIRT2. we synthesized and screened over 35 synthesized 
analogues of the type B PPAP natural product clusianone 
and the type A PPAP natural product nemorosone (see Fig. 1 
for details and structures). Among the synthesized PPAP 
analogues, we identified five compounds with SIRT1 inhibi-
tory activity with IC50 ranging from 30 to 90 µM, including 
JQ-101, JQ-3, BM1810, BM1817 and BM1847 (Fig. 2). One of 
these compounds, designated JQ-101, which showed the best 
in vitro activity for inhibition of SIRT1, forms the major focus 
of this report.
Inhibition of SIRT1 deacetylase activity by JQ-101 in vitro 
and in vivo. Using a fluorogenic substrate, we performed 
biochemical-based inhibition assays with recombinant 
SIRT1 and SIRT2. JQ-101 inhibited SIRT1 deacetylase 
activity with an IC50 of 30 µM (Fig. 3A and B). JQ-101 also 
inhibited the closely-related class III HDAC SIRT2, with an 
IC50 of 150 µM (Fig. 3C). Thus, JQ-101 has 5-fold selectivity 
in inhibiting SIRT1 over SIRT2. Sirtinol was used as a posi-
tive control for the assay, with an IC50 value of 60 µM for 
SIRT1 (Fig. 3B) and 20 µM for SIRT2 (Fig. 3C), respectively, 
in good agreement with reported values.
we next examined whether JQ-101 can target SIRT1 in a 
cell-based system. It is well established that lysine 382 of p53 
is a cellular substrate of SIRT1 (46). we therefore assessed 
the levels of lysine 382-acetylated p53 in p53 wild-type cells 
exposed to JQ-101 compared to vehicle. Treatment with JQ-101 
increased the acetylation levels of p53 in LNCaP and H460 
cells (Fig. 3D and E). we also assessed the level of histone 
H4 acetylation at lysine 16, another confirmed substrate for 
SIRT1. JQ-101 treatment increased the levels of histone H4 
acetylation in both H460 (p53 wt) and H1299 (p53 null) cells 
(Fig. 3E and F). These findings suggest that JQ-101 can prevent 
the deacetylation of known biological substrates of SIRT1, 
thereby demonstrating on-target SIRT1 inhibitory activity of 
JQ-101 in vivo.
JQ-101 suppresses cancer cells growth. Several SIRT1 
inhibitors have been shown to produce antitumor activity 
in vitro and in mouse xenograft models. To investigate the 
effects of JQ-101 on cancer cell growth and survival inhibi-
tion, we determined the inhibitory ability of JQ -101 on a panel 
of human cancer cell lines, with normal human cell lines as 
Figure 2. Compounds with SIRT1 inhibitory activity. A biochemical-based inhibitory assay with recombinant SIRT1 and SIRT2 was performed. Five compounds 
show SIRT1 inhibition activity with IC50 from 30 to 90 µM.
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serving as non-cancer controls. As shown in Fig. 4A and B, 
JQ-101 suppressed LNCaP and H460 tumor cell growth in a 
dose-dependent manner. we screened eight different cancer 
cell lines in total, including lines derived from prostate cancers 
(LNCaP and PC3), lung cancers (H460 and A549), leukemia 
(Jurkat), lymphoma (Ramos), and breast cancers (ZR75 and 
MDA231). JQ-101 suppressed tumor cell growth at IC50 values 
ranging from 20 to 119 µM (Table I). By comparison, JQ-101 
was much less toxic in normal human cells, including one 
normal human prostate epithelial cell line (PZ-HPv-7) and 
one human lung fibroblast cell line (MRC-5) (Table I). These 
results suggest that JQ-101 exerts cancer cell-selectivity in 
inhibiting the growth of cells.
To more specifically study the role of SIRT1 in control of 
cancer cell growth, SIRT1 was knocked down with SIRT1 
RNAi in LNCaP and H460 cells. SIRT1 silencing resulted in 
cancer cell growth suppression (Fig. 4C). This suggests that 
SIRT1 is important in control of growth in these cancer cells. 
To further study the specificity of JQ-101 mediated cancer 
cell growth, we treated the both SIRT1-silenced and vector 
control-transfected H460 cancer cell lines with JQ-101. The 
effect of JQ-101 on cancer cell growth is greatly attenuated in 
the SIRT1-silenced cells (Fig. 4D). This suggests that JQ-101 
suppresses cancer cell growth by targeting SIRT1.
JQ-101 induces both apoptosis and cell senescence. To 
further elucidate the molecular mechanisms of this tumor-
selective growth suppression, Annexin v and β-gal staining 
were carried out to study the effects of JQ-101 in inducing 
apoptosis or cell senescence. JQ-101 treatment induced cell 
death and apoptosis in LNCaP cells; proportions of cells 
in both late stage (14.5%) and early stage (3.2%) apoptosis 
increased after JQ-101 treatment (Fig. 5A). In contrast, 
apoptosis was not observed in H1299 cells (data not shown); 
instead, JQ-101 treatment induced cell senescence in H1299 
cells (Fig. 5B) but not in LNCaP cells (data not shown). This 
suggests that the induction of either apoptosis or cell senes-
cence, in a context-dependent fashion, are the mechanisms 
whereby JQ-101 suppresses cancer cell growth and survival.
JQ-101 inhibits cancer cell invasion. Recent studies have 
shown that SIRT1 plays an important role in cancer cell 
migration and invasion (14,16,46). we therefore determined 
whether SIRT1 inhibition by JQ-101 could inhibit cancer cell 
invasion. PC3 prostate cancer and A549 lung cancer cells, 
which exhibit invasive behavior, were exposed to JQ-101, and 
the effects on cancer cell invasion were quantitated, using 
a  Transwell chamber assay system with matrigel coated on 
the top of an ECM-like membrane to prevent the transmigra-
tion of non-invasive cells. Exposure to JQ-101 significantly 
decreased invasion compared to vehicle control, producing a 
3.5-fold reduction in PC3 cell invasion and a 4.2-fold reduc-
tion in A549 cells (Fig. 6A and B), suggesting that JQ-01 
exerts an inhibitory effect on cancer cell invasion.
Figure 3. Identification of JQ-101 as a selective SIRT1 inhibitor. (A) Chemical structure of JQ-101. (B and C) In vitro SIRT1 and SIRT2 inhibition assays. Recombinant 
human SIRT1 and SIRT2 were exposed to various concentrations of JQ-101 and sirtinol as indicated, and their relative inhibitory potential (against DMSO as vehicle 
control) was analyzed and displayed as a percentage of SIRT1 activity. JQ-101 inhibited recombinant SIRT1 and SIRT2 deacetylase activity at an IC50 of 30 and 
150 µM, respectively. Sirtinol was included as a positive control. The IC50 determination of JQ-101 was performed using GraphPad Prism 6.0. Each point represents 
the  mean of three independent experiments; error bars indicate SD. (D and E) JQ-101 increases levels of lysine 382 acetylated p53. The human prostate cancer cell 
line (D) LNCaP and (E) H460 were treated with JQ-101 at 50 µM or sirtinol at 50 µM or vehicle control for 2 h. Cell lysates were prepared and immunoblotted 
with anti-Ac-p53, p53 or β-actin antibodies. (F and G) JQ-101 increased levels of histone H4 acetylated at lysine 16. (F) H460 and (G) H1299 cells were treated with 
JQ-101 at 50 µM or sirtinol at 50 µM or vehicle control for 2 h. Cell lysates were prepared and immunoblotted with anti-Ac-H4K16, anti-H4 or β-actin antibodies.
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Figure 4. JQ-101 suppresses tumor cells growth and survival. (A and B) Cells from the prostate cancer line LNCaP or lung cancer line H460 were treated with 
varying concentrations of JQ-101 as indicated in the graph for 72 h, or vehicle control (DMSO) and MTS assay was performed. The error bars indicate the SEM. 
(C) SIRT1 silencing suppressed both LNCaP and H460 cell growth and survival. A total of 2x104 SIRT-silenced or shRNA-control LNCaP or H460 cells were 
seeded onto 24-well plates and counted after 72 h of culture. The error bars indicate the SEM. (D) SIRT1 knockdown reduces the inhibitory effects of JQ-101 
on H460 proliferation. A total of 2x104 SIRT-silenced or shRNA-control H460 cells were seeded onto 24-well plates, treated with 50 µM JQ-101 for 3 days and 
viable cells were enumerated. The error bars indicate the SEM. Asterisks indicate significant differences between experimental versus control group (*p<0.05). 
(E) Immunoblot analysis shows the SIRT1 levels in the LNCap and H460 knockdown cells that were used for the cell proliferation analysis in (C and D).
Figure 5. JQ-101 induces either apoptosis or cell senescence. (A) JQ-101 induces apoptosis in prostate LNCaP cells. LNCaP cells were treated with JQ-101 (50 µM) 
or vehicle control for 72 h. The cells were collected, labeled with Annexin V antibody/PI, and analyzed with flow cytometry. UL, dead cells; UR, late apoptosis; 
LL, live cells; LR, early apoptosis. (B) The lung cancer cell lines H460 was seeded at approximately 50% confluence and exposed to JQ-101 at 50 µM for 3 days. 
X-Gal-based β-galactosidase staining was performed. The β-galactosidase staining-positive cells were quantitated by microscopy and the percentage of SA-β-Gal 
positive cells was calculated. The histograms represent the mean ± SD of triplicates. Asterisks indicate significant differences between two groups (*p<0.01).
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Discussion
SIRT1 has attracted much attention for its functional roles in 
cancer (47). we report here a new SIRT1 inhibitor JQ-101, a 
compound possessing a polyprenylated acylphloroglucinol 
(PPAP) core, which exhibits selective inhibition of tumor cell 
line growth and survival though induction of apoptosis and 
cellular senescence, and significantly suppresses cancer cell 
invasion.
To date, several SIRT1 inhibitors have been developed 
with a broad range of  potency in SIRT1 inhibition (32-36). 
The IC50 for JQ-101 against STIR1 is approximately 30 µM, 
a potency similar to several of the previously reported SIRT1-
inhibitory compounds, including sirtinol (31), cambinol (32), 
salermide (37), tenovin-6 (34) and splitomycin (35). Most of 
the SIRT1 inhibitors identified previously also possess SIRT2 
inhibitory activity, due to the high level of sequence similarity 
between SIRT1 and SIRT2. while JQ-101 also exhibited 
inhibitory effects on SIRT2, 5-fold higher concentrations were 
necessary, making JQ-101 somewhat SIRT1-specific. Our 
results show that JQ-101 can inhibit the growth and survival 
of a panel of cancer cell lines. Although we cannot rule out 
the possibility that minor inhibitory effects of SIRT 2 activity 
may contribute in part to the observed selective cytotoxicity 
of JQ-101, these studies were carried out under conditions far 
below the IC50 for SIRT2. In addition, our results show that 
SIRT1 knockdown greatly impairs the effect of JQ-101 on cell 
growth and survival (Fig. 4D), demonstrating that SIRT1 is the 
major target of JQ-101.
It has been shown that SIRT1 inhibition can induce apoptosis 
in many cancer cell types, in particular p53-wild-type cells 
(45,48-50); alternatively, SIRT1 inhibition can also induce cell 
senescence (51-53). Our results show that JQ-101 can trigger 
either apoptosis in p53-wild-type LNCaP cells or induce cell 
senescence in p53-null H1299 cells (Fig. 5). Depending upon 
the specific genetic background of the cancer cell, SIRT1 
inhibition by JQ-101 may utilize different downstream targets 
of SIRT1 to induce either apoptosis or cell senescence, to 
suppress cancer cell growth and survival.
we also show in this study that JQ-101 treatment can 
greatly reduce cancer cell invasion (Fig. 6). we have previously 
identified SIRT1 as a positive regulator of epithelial-to-
mesenchymal transition (EMT), cell invasion, and metastatic 
growth of prostate cancer cells, and put forward SIRT1 as a 
potential therapeutic target to reverse EMT and to prevent 
prostate cancer progression (8,19). Consistent with our find-
ings, it has been shown that SIRT1 inhibition reduces cancer 
cell migration and invasion while SIRT1 activation promotes 
cancer metastasis (12,15,23,54). These results suggest that 
SIRT1 plays an important role in cancer invasion and metas-
tasis, and that development of SIRT1 inhibitors may represent 
a critical new targeted strategy to prevent cancer metastasis 
and progression.
Given our findings that JQ-101 can selectively suppress 
cancer cell growth by inducing tumor cell apoptosis and 
senescence, and significantly inhibit cancer cell invasion, these 
results suggest a potential role of JQ-101 or a derivative in a 
SIRT1-targeted approach to cancer therapy. Studies are under 
Figure 6. JQ-101 decreases cancer cell invasion. A total of 2.5x104 (A) PC3 or (B) A549 cells in 500 µl medium mixed with JQ-101 (50 µM) or vehicle were 
loaded onto transwells coated with matrigel. After 48-h incubation at 37˚C, the transwells were removed from 24-well plates and stained. The invading cells were 
quantitated by light microscopy. A representative experiment from three independent experiments is shown. Asterisks indicate significant differences between two 
groups (*p<0.05).
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way to delineate the effects of JQ-101 on tumor formation, 
growth and metastasis in mouse models in vivo. JQ-101 will 
also serve as a novel chemical scaffold for future development 
of more potent SIRT1 inhibitors to be used in cancer treatment.
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